BioNTech SE Stock

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-12 EDT Pre-market 07:46:55
97.91 USD -0.90% Intraday chart for BioNTech SE 97.46 -0.46%

Financials

Sales 2024 * 2.75B 2.96B 4.07B Sales 2025 * 2.75B 2.97B 4.08B Capitalization 21.78B 23.49B 32.3B
Net income 2024 * -419M -452M -621M Net income 2025 * -548M -591M -813M EV / Sales 2024 * 3.32 x
Net cash position 2024 * 12.67B 13.67B 18.8B Net cash position 2025 * 12.02B 12.96B 17.83B EV / Sales 2025 * 3.55 x
P/E ratio 2024 *
-49.9 x
P/E ratio 2025 *
-39.5 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa MT
BioNTech gets $145 mln funding for African vaccine plants RE
BioNTech and CEPI Expand Partnership to Strengthen Africa?s mRNA Vaccine Ecosystem CI
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants RE
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
BioNTech Collaborating with MediLink to Develop More Potential Antibody-Drug Conjugate, Immunotherapy Treatments MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
More news
1 day-0.46%
1 week-4.48%
Current month-2.67%
1 month+6.81%
3 months+2.28%
6 months-0.75%
Current year-7.23%
More quotes
1 week
97.11
Extreme 97.1101
101.96
1 month
90.24
Extreme 90.24
104.33
Current year
85.21
Extreme 85.2129
114.70
1 year
85.21
Extreme 85.2129
125.83
3 years
85.21
Extreme 85.2129
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 70 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-06-12 97.91 -0.90% 510,824
24-06-11 98.8 +0.84% 476,592
24-06-10 97.98 -2.35% 652,317
24-06-07 100.3 -1.44% 377,870
24-06-06 101.8 -0.67% 618,739

Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
90.26 EUR
Average target price
103.4 EUR
Spread / Average Target
+14.55%
Consensus